Interleukin-6 and prostate cancer: Current developments and unsolved questions.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Interleukin-6 (IL-6) is a pro-inflammatory cytokine found in prostate tumors.
• IL-6 influences tumor cell proliferation, apoptosis, angiogenesis, and differentiation.
• The IL-6/Janus kinase/signal transducer and activator of transcription (STAT)3 pathway is a target for prostate cancer (PCa) treatment.

Purpose of the Study:

• To investigate the multifaceted role of IL-6 and STAT3 in prostate cancer.
• To evaluate the potential of blocking the IL-6/STAT3 pathway for improved PCa treatment.
• To understand IL-6's role in cellular stemness and resistance to therapies like enzalutamide.

Main Methods:

• Review of existing research on IL-6 and STAT3 signaling in PCa models.
• Analysis of experimental therapies targeting the IL-6/STAT3 pathway, including siltuximab.
• Examination of endogenous IL-6 inhibitors and their effects.

Main Results:

• Siltuximab inhibited prostate tumor growth in vitro and in vivo, delaying castration resistance.
• Anti-IL-6 antibody monotherapy showed limited clinical success in metastatic PCa.
• IL-6 contributes to cellular stemness and resistance to enzalutamide by increasing STAT3 phosphorylation.

Conclusions:

• The IL-6/STAT3 pathway is complex in PCa, with varied effects on tumor growth.
• Targeting IL-6 requires an individualized approach, potentially in combination with standard treatments.
• Identifying patients who will benefit from anti-IL-6 therapy is crucial for clinical success.